Annexon, Inc. (ANNX)
4.01
+0.60
(+17.60%)
USD |
NASDAQ |
Oct 19, 16:00
4.09
+0.08
(+2.00%)
After-Hours: 20:00
Annexon Shareholders Equity (Quarterly) : 186.06M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 186.06M |
| March 31, 2026 | 204.53M |
| December 31, 2025 | 211.65M |
| September 30, 2025 | 161.44M |
| June 30, 2025 | 199.02M |
| March 31, 2025 | 243.79M |
| December 31, 2024 | 293.10M |
| September 30, 2024 | 331.56M |
| June 30, 2024 | 361.08M |
| March 31, 2024 | 262.40M |
| December 31, 2023 | 250.56M |
| September 30, 2023 | 156.84M |
| June 30, 2023 | 184.72M |
| March 31, 2023 | 214.86M |
| December 31, 2022 | 231.19M |
| September 30, 2022 | 260.60M |
| Date | Value |
|---|---|
| June 30, 2022 | 168.04M |
| March 31, 2022 | 200.61M |
| December 31, 2021 | 231.91M |
| September 30, 2021 | 264.48M |
| June 30, 2021 | 295.34M |
| March 31, 2021 | 321.48M |
| December 31, 2020 | 344.28M |
| September 30, 2020 | 365.48M |
| June 30, 2020 | 117.18M |
| March 31, 2020 | 31.84M |
| December 31, 2019 | 43.53M |
| September 30, 2019 | -91.76M |
| June 30, 2019 | -81.89M |
| March 31, 2019 | |
| December 31, 2018 | -64.20M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 246.07M |
| Total Liabilities (Quarterly) | 60.01M |
| Debt to Equity Ratio | 0.1325 |
| Current Ratio | 5.529 |
| Net Debt Paydown Yield | 0.07% |